Experimental studies suggested that inhibition of leptin or IL-6-JAK/STAT3 signaling in CRPC-cells enhances the anti-tumor NKCC via alteration of PD-L1/NKG2D-ligands levels [65,134,136]. This evidence concerns the gene IL6 and neoplasm.